Veronique Lecault - 01 Jan 2025 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role
Chief Operating Officer, Director
Signature
Tryn Stimart, attorney-in-fact
Issuer symbol
ABCL
Transactions as of
01 Jan 2025
Transactions value $
$0
Form type
4
Filing time
03 Jan 2025, 15:40:45 UTC
Previous filing
24 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABCL Share option (right to buy) Award $0 +832,033 +21.7% $0.000000 4,661,804 01 Jan 2025 Common Shares 832,033 $2.93 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.